ImmunoCellular Therapeutics, Ltd.
IMUC
IMUC was delisted on the 16th of October, 2018.
34 hedge funds and large institutions have $3.48M invested in ImmunoCellular Therapeutics, Ltd. in 2016 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 5 increasing their positions, 6 reducing their positions, and 2 closing their positions.
300% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 2
21% more funds holding
Funds holding: 28 → 34 (+6)
2% more capital invested
Capital invested by funds: $3.41M → $3.48M (+$70K)
17% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
B
Bailard
Foster City,
California
|
+$633K |
| 2 |
CI
Cowen Inc
New York
|
+$63.5K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$36.3K |
| 4 |
Renaissance Technologies
New York
|
+$19.6K |
| 5 |
GC
Guggenheim Capital
Chicago,
Illinois
|
+$5.25K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$9.16K |
| 2 |
VKH
Virtu KCG Holdings
New York
|
-$5.16K |
| 3 |
GF
Gerstein Fisher
New York
|
-$5K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$4.56K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$3.79K |
IMUC Hedge Fund Activity: Q1 2016 in Review
34 of the 3,767 institutional investors tracked by Wall St. Rank reported a position in ImmunoCellular Therapeutics, Ltd. (IMUC) for Q1 2016, worth a combined $3.48M — up 2.1% from $3.41M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new IMUC positions and 2 closed out — a net gain of 6 holders — while 5 added to existing stakes and 6 trimmed.
The largest buyer was Bailard, opening a new position worth an estimated $633K. The largest seller was Sabby Management, cutting an estimated $9.16K.
- 34 institutional investors held ImmunoCellular Therapeutics, Ltd. (IMUC) as of Q1 2016, up from 28 in Q4 2015.
- Funds reported $3.48M of ImmunoCellular Therapeutics, Ltd. stock for Q1 2016, up 2.1% quarter-over-quarter.
- 8 funds opened new ImmunoCellular Therapeutics, Ltd. positions in Q1 2016 and 2 closed out, a net change of +6 holders.
- The largest ImmunoCellular Therapeutics, Ltd. buyer in Q1 2016 was Bailard, an estimated $633K added.
- The largest ImmunoCellular Therapeutics, Ltd. seller in Q1 2016 was Sabby Management, an estimated $9.16K sold.
Based on aggregated 13F filings for Q1 2016.